Drug Exclusivity, Incentives On The Table As House 'Cures' Effort Advances

The brand drug industry and some patient groups have lined up proposals for added drug exclusivity as House lawmakers consider medical product development and regulatory reforms outside the Prescription Drug User Fee Act negotiation process, but generic drug makers, AARP and a key House Democrat urge Congress to tread carefully. Energy and Commerce health panel chair Joe Pitts (R-PA) recently said company incentives could be included in an upcoming bill stemming from the committee's 21st Century Cures initiative, and stakeholders...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.